Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4504898 | 1.00 | HRH3 (0.70) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT | |
| SCHEMBL7374716 | 0.97 | HRH3 (0.75) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT | |
| SCHEMBL9158672 | 0.97 | HRH3 (0.75) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT | |
| SCHEMBL1404023 | 0.97 | HRH3 (0.75) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT | |
| SCHEMBL11859421 | 0.97 | HRH3 (0.75) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT | |
| SCHEMBL1403869 | 0.97 | HRH3 (0.75) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT | |
| SCHEMBL1404029 | 0.97 | HRH3 (0.75) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT | |
| SCHEMBL1404107 | 0.97 | HRH3 (0.75) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT | |
| SCHEMBL3191128 | 0.97 | HRH3 (0.67) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT | |
| Hydrochloric Acid SCHEMBL28153477 | 0.97 | HRH3 (0.67) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 417 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4667511-A2 | DENDRITIC ARCHITECTURES AS NONVIRAL VECTORS IN GENE DELIVERY | Tiba Biotech LLC (US) | 2025-12-24 | — | — | EP | claimed |
| US-20240207187-A1 | DENDRITIC ARCHITECTURES AS NONVIRAL VECTORS IN GENE DELIVERY | TIBA BIOTECH LLC (US) | 2024-06-27 | — | — | US | claimed |
| CN-117915958-A | Dendritic structures as non-viral vectors in gene delivery | 蒂巴生物技术有限公司 | 2024-04-19 | — | — | CN | claimed |
| EP-4313170-A1 | DENDRITIC ARCHITECTURES AS NONVIRAL VECTORS IN GENE DELIVERY | Tiba Biotech LLC (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2022212838-A1 | DENDRITIC ARCHITECTURES AS NONVIRAL VECTORS IN GENE DELIVERY | TIBA BIOTECH LLC (US) | 2022-10-06 | — | — | WO | claimed |
| EP-1399409-B1 | METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS | BASF SE (DE) | 2012-10-31 | — | — | EP | claimed |
| US-7973164-B2 | Quinoline derivatives | ASTRAZENECA AB (SE) | 2011-07-05 | — | — | US | claimed |
| US-20090233950-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | claimed |
| EP-1773860-A4 | METHODS FOR IDENTIFYING RISK OF TYPE II DIABETES AND TREATMENTS THEREOF | SEQUENOM INC (US) | 2009-05-06 | — | — | EP | claimed |
| US-20090076075-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | claimed |
| WO-2003008409-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-01-30 | — | — | WO | claimed |
| WO-2002092579-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-21 | — | — | WO | claimed |
| WO-2002085895-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-10-31 | — | — | WO | claimed |
| WO-2002030924-A1 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | claimed |
| WO-2002030926-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | claimed |
| WO-2002016352-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-02-28 | — | — | WO | claimed |
| EP-0885198-B1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-12-19 | — | — | EP | claimed |
| US-6291455-B1 | PRODUCING AN ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY REDUCING EFFECT | ZENECA LIMITED (GB) | 2001-09-18 | — | — | US | claimed |
| EP-0885198-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-12-23 | — | — | EP | claimed |
| WO-1997032856-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-09-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207187-A1 | DENDRITIC ARCHITECTURES AS NONVIRAL VECTORS IN GENE DELIVERY | TLR3, TLR9, TLR6 | HRH3 2092/4885CYP1A2 4879/4885MAPK1 4157/4885 |
| US-20090076075-A1 | QUINOLINE DERIVATIVES | RECQL, NQO2, NRAS | HRH3 228/4885CYP1A2 483/4885MAPK1 602/4885 |
| US-20090233950-A1 | QUINAZOLINE DERIVATIVES | NQO2, CCNI, F12 | HRH3 169/4885CYP1A2 546/4885MAPK1 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.